Ubs Oconnor LLC Inhibrx, Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $567,278 - $930,523	33,448 New	33,448 $868 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $1.05 Million - $1.55 Million	-57,000 Reduced 64.19%	31,800 $600,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $353,210 - $583,374	17,503 Added 24.55%	88,800 $0
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $159,259 - $340,111	-13,753 Reduced 16.17%	71,297 $1.28 Billion
Q2 2022 Aug 12, 2022	BUY	$8.52 - $25.26 $724,626 - $2.15 Million	85,050 New	85,050 $965,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $565M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.